ID   AT2A2_HUMAN             Reviewed;        1042 AA.
AC   P16615; A6NDN7; B4DF05; P16614; Q86VJ2;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1990, sequence version 1.
DT   07-APR-2021, entry version 239.
DE   RecName: Full=Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 {ECO:0000305};
DE            Short=SERCA2;
DE            Short=SR Ca(2+)-ATPase 2;
DE            EC=7.2.2.10 {ECO:0000269|PubMed:28890335};
DE   AltName: Full=Calcium pump 2;
DE   AltName: Full=Calcium-transporting ATPase sarcoplasmic reticulum type, slow twitch skeletal muscle isoform;
DE   AltName: Full=Endoplasmic reticulum class 1/2 Ca(2+) ATPase;
GN   Name=ATP2A2 {ECO:0000312|HGNC:HGNC:812}; Synonyms=ATP2B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Kidney;
RX   PubMed=2844796;
RA   Lytton J., Maclennan D.H.;
RT   "Molecular cloning of cDNAs from human kidney coding for two alternatively
RT   spliced products of the cardiac Ca2+-ATPase gene.";
RL   J. Biol. Chem. 263:15024-15031(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 84-1042 (ISOFORM 4).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 954-1042 (ISOFORM 3), AND TISSUE SPECIFICITY.
RX   PubMed=12659872; DOI=10.1016/s0006-291x(03)00405-4;
RA   Gelebart P., Martin V., Enouf J., Papp B.;
RT   "Identification of a new SERCA2 splice variant regulated during monocytic
RT   differentiation.";
RL   Biochem. Biophys. Res. Commun. 303:676-684(2003).
RN   [6]
RP   INTERACTION WITH TRAM2.
RX   PubMed=14749390; DOI=10.1128/mcb.24.4.1758-1768.2004;
RA   Stefanovic B., Stefanovic L., Schnabl B., Bataller R., Brenner D.A.;
RT   "TRAM2 protein interacts with endoplasmic reticulum Ca2+ pump Serca2b and
RT   is necessary for collagen type I synthesis.";
RL   Mol. Cell. Biol. 24:1758-1768(2004).
RN   [7]
RP   NITRATION AT TYR-294 AND TYR-295.
RX   PubMed=16399855; DOI=10.1152/ajpheart.01293.2005;
RA   Xu S., Ying J., Jiang B., Guo W., Adachi T., Sharov V., Lazar H.,
RA   Menzoian J., Knyushko T.V., Bigelow D., Schoeneich C., Cohen R.A.;
RT   "Detection of sequence-specific tyrosine nitration of manganese SOD and
RT   SERCA in cardiovascular disease and aging.";
RL   Am. J. Physiol. 290:H2220-H2227(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-663, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-663, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   INTERACTION WITH HAX1.
RX   PubMed=18971376; DOI=10.1091/mbc.e08-06-0587;
RA   Vafiadaki E., Arvanitis D.A., Pagakis S.N., Papalouka V., Sanoudou D.,
RA   Kontrogianni-Konstantopoulos A., Kranias E.G.;
RT   "The anti-apoptotic protein HAX-1 interacts with SERCA2 and regulates its
RT   protein levels to promote cell survival.";
RL   Mol. Biol. Cell 20:306-318(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-663, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   INTERACTION WITH SLC35G1 AND STIM1.
RX   PubMed=22084111; DOI=10.1073/pnas.1117231108;
RA   Krapivinsky G., Krapivinsky L., Stotz S.C., Manasian Y., Clapham D.E.;
RT   "POST, partner of stromal interaction molecule 1 (STIM1), targets STIM1 to
RT   multiple transporters.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:19234-19239(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-663, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-580 AND SER-663, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   INTERACTION WITH TMEM203.
RX   PubMed=25996873; DOI=10.1371/journal.pone.0127480;
RA   Shambharkar P.B., Bittinger M., Latario B., Xiong Z., Bandyopadhyay S.,
RA   Davis V., Lin V., Yang Y., Valdez R., Labow M.A.;
RT   "TMEM203 is a novel regulator of intracellular calcium homeostasis and is
RT   required for spermatogenesis.";
RL   PLoS ONE 10:E0127480-E0127480(2015).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [19]
RP   VARIANTS DD.
RX   PubMed=10441323; DOI=10.1093/hmg/8.9.1611;
RA   Sakuntabhai A., Burge S., Monk S., Hovnanian A.;
RT   "Spectrum of novel ATP2A2 mutations in patients with Darier's disease.";
RL   Hum. Mol. Genet. 8:1611-1619(1999).
RN   [20]
RP   VARIANTS DD, AND TISSUE SPECIFICITY.
RX   PubMed=10441324; DOI=10.1093/hmg/8.9.1621;
RA   Ruiz-Perez V.L., Carter S.A., Healy E., Todd C., Rees J.L., Steijlen P.M.,
RA   Carmichael A.J., Lewis H.M., Hohl D., Itin P., Vahlquist A., Gobello T.,
RA   Mazzanti C., Reggazini R., Nagy G., Munro C.S., Strachan T.;
RT   "ATP2A2 mutations in Darier's disease: variant cutaneous phenotypes are
RT   associated with missense mutations, but neuropsychiatric features are
RT   independent of mutation class.";
RL   Hum. Mol. Genet. 8:1621-1630(1999).
RN   [21]
RP   VARIANTS DD THR-39; ARG-560 AND LEU-765.
RX   PubMed=10441325; DOI=10.1093/hmg/8.9.1631;
RA   Jacobsen N.J.O., Lyons I., Hoogendoorn B., Burge S., Kwok P.-Y.,
RA   O'Donovan M.C., Craddock N., Owen M.J.;
RT   "ATP2A2 mutations in Darier's disease and their relationship to
RT   neuropsychiatric phenotypes.";
RL   Hum. Mol. Genet. 8:1631-1636(1999).
RN   [22]
RP   VARIANTS DD GLU-23; LYS-357; PHE-495 AND ARG-749.
RX   PubMed=10080178; DOI=10.1038/6784;
RA   Sakuntabhai A., Ruiz-Perez V., Carter S., Jacobsen N., Burge S., Monk S.,
RA   Smith M., Munro C.S., O'Donovan M.C., Craddock N., Kucherlapati R.,
RA   Rees J.L., Owen M.J., Lathrop G.M., Monaco A.P., Strachan T., Hovnanian A.;
RT   "Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease.";
RL   Nat. Genet. 21:271-277(1999).
RN   [23]
RP   VARIANT AKV LEU-602.
RX   PubMed=12542527; DOI=10.1046/j.1523-1747.2003.t01-1-12045.x;
RA   Dhitavat J., Macfarlane S., Dode L., Leslie N., Sakuntabhai A.,
RA   MacSween R., Saihan E., Hovnanian A.;
RT   "Acrokeratosis verruciformis of Hopf is caused by mutation in ATP2A2:
RT   evidence that it is allelic to Darier's disease.";
RL   J. Invest. Dermatol. 120:229-232(2003).
RN   [24]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=16402920; DOI=10.1042/bj20051427;
RA   Dally S., Bredoux R., Corvazier E., Andersen J.P., Clausen J.D., Dode L.,
RA   Fanchaouy M., Gelebart P., Monceau V., Del Monte F., Gwathmey J.K.,
RA   Hajjar R., Chaabane C., Bobe R., Raies A., Enouf J.;
RT   "Ca2+-ATPases in non-failing and failing heart: evidence for a novel
RT   cardiac sarco/endoplasmic reticulum Ca2+-ATPase 2 isoform (SERCA2c).";
RL   Biochem. J. 395:249-258(2006).
RN   [25]
RP   FUNCTION, INTERACTION WITH SLN; PLN; VMP1 AND ULK1, CATALYTIC ACTIVITY,
RP   MUTAGENESIS OF PHE-256, AND ACTIVITY REGULATION.
RX   PubMed=28890335; DOI=10.1016/j.molcel.2017.08.005;
RA   Zhao Y.G., Chen Y., Miao G., Zhao H., Qu W., Li D., Wang Z., Liu N., Li L.,
RA   Chen S., Liu P., Feng D., Zhang H.;
RT   "The ER-Localized Transmembrane Protein EPG-3/VMP1 Regulates SERCA Activity
RT   to Control ER-Isolation Membrane Contacts for Autophagosome Formation.";
RL   Mol. Cell 67:974.e6-989.e6(2017).
RN   [26]
RP   INTERACTION WITH TMX2.
RX   PubMed=31735293; DOI=10.1016/j.ajhg.2019.10.009;
RA   Vandervore L.V., Schot R., Milanese C., Smits D.J., Kasteleijn E.,
RA   Fry A.E., Pilz D.T., Brock S., Boerklue-Yuecel E., Post M.,
RA   Bahi-Buisson N., Sanchez-Soler M.J., van Slegtenhorst M., Keren B.,
RA   Afenjar A., Coury S.A., Tan W.H., Oegema R., de Vries L.S., Fawcett K.A.,
RA   Nikkels P.G.J., Bertoli-Avella A., Al Hashem A., Alwabel A.A.,
RA   Tlili-Graiess K., Efthymiou S., Zafar F., Rana N., Bibi F., Houlden H.,
RA   Maroofian R., Person R.E., Crunk A., Savatt J.M., Turner L., Doosti M.,
RA   Karimiani E.G., Saadi N.W., Akhondian J., Lequin M.H., Kayserili H.,
RA   van der Spek P.J., Jansen A.C., Kros J.M., Verdijk R.M., Milosevic N.J.,
RA   Fornerod M., Mastroberardino P.G., Mancini G.M.S.;
RT   "TMX2 is a crucial regulator of cellular redox state, and its dysfunction
RT   causes severe brain developmental abnormalities.";
RL   Am. J. Hum. Genet. 105:1126-1147(2019).
RN   [27]
RP   VARIANT DD LEU-41 DEL.
RX   PubMed=19995371; DOI=10.1111/j.1365-2133.2009.09580.x;
RA   Tsuruta D., Akiyama M., Ishida-Yamamoto A., Imanishi H., Mizuno N.,
RA   Sowa J., Kobayashi H., Ishii M., Kurokawa I., Shimizu H.;
RT   "Three-base deletion mutation c.120_122delGTT in ATP2A2 leads to the unique
RT   phenotype of comedonal Darier disease.";
RL   Br. J. Dermatol. 162:687-689(2010).
RN   [28]
RP   VARIANTS DD 74-VAL--GLN-108 DEL; SER-101; GLN-131; 194-VAL--PRO-197 DEL;
RP   PRO-590; ALA-625; GLU-626; 666-ARG--SER-1042 DEL; PRO-672; PRO-691;
RP   TRP-750; TRP-765; GLY-849 INS; PRO-900 AND ARG-943.
RX   PubMed=28035777; DOI=10.1002/humu.23164;
RG   European Professional Contributors;
RA   Nellen R.G., Steijlen P.M., van Steensel M.A., Vreeburg M., Frank J.,
RA   van Geel M.;
RT   "Mendelian Disorders of Cornification Caused by Defects in Intracellular
RT   Calcium Pumps: Mutation Update and Database for Variants in ATP2A2 and
RT   ATP2C1 associated with Darier disease and Hailey-Hailey disease.";
RL   Hum. Mutat. 38:343-356(2017).
CC   -!- FUNCTION: This magnesium-dependent enzyme catalyzes the hydrolysis of
CC       ATP coupled with the translocation of calcium from the cytosol to the
CC       sarcoplasmic reticulum lumen (PubMed:16402920). Involved in autophagy
CC       in response to starvation. Upon interaction with VMP1 and activation,
CC       controls ER-isolation membrane contacts for autophagosome formation
CC       (PubMed:28890335). Also modulates ER contacts with lipid droplets,
CC       mitochondria and endosomes (PubMed:28890335).
CC       {ECO:0000269|PubMed:16402920, ECO:0000269|PubMed:28890335}.
CC   -!- FUNCTION: [Isoform 2]: Involved in the regulation of the
CC       contraction/relaxation cycle. Acts as a regulator of TNFSF11-mediated
CC       Ca(2+) signaling pathways via its interaction with TMEM64 which is
CC       critical for the TNFSF11-induced CREB1 activation and mitochondrial ROS
CC       generation necessary for proper osteoclast generation. Association
CC       between TMEM64 and SERCA2 in the ER leads to cytosolic Ca(2+) spiking
CC       for activation of NFATC1 and production of mitochondrial ROS, thereby
CC       triggering Ca(2+) signaling cascades that promote osteoclast
CC       differentiation and activation. {ECO:0000250|UniProtKB:O55143}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + Ca(2+)(in) + H2O = ADP + Ca(2+)(out) + H(+) + phosphate;
CC         Xref=Rhea:RHEA:18105, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:29108, ChEBI:CHEBI:30616, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:456216; EC=7.2.2.10;
CC         Evidence={ECO:0000269|PubMed:28890335};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:18106;
CC         Evidence={ECO:0000269|PubMed:28890335};
CC   -!- ACTIVITY REGULATION: Has different conformational states with
CC       differential Ca2+ affinity. The E1 conformational state (active form)
CC       shows high Ca(2+) affinity, while the E2 state exhibits low Ca(2+)
CC       affinity. Reversibly inhibited by phospholamban (PLN) at low calcium
CC       concentrations. Inhibited by sarcolipin (SLN) and myoregulin (MRLN).
CC       The inhibition is blocked by VMP1 (PubMed:28890335). Enhanced by DWORF;
CC       DWORF increases activity by displacing sarcolipin (SLN), phospholamban
CC       (PLN) and myoregulin (MRLN) (By similarity). Stabilizes SERCA2 in its
CC       E2 state (PubMed:28890335). {ECO:0000250|UniProtKB:O55143,
CC       ECO:0000250|UniProtKB:P04191, ECO:0000250|UniProtKB:Q8R429,
CC       ECO:0000269|PubMed:28890335}.
CC   -!- SUBUNIT: Interacts with sarcolipin (SLN); the interaction inhibits
CC       ATP2A2 Ca(2+) affinity (PubMed:28890335). Interacts with phospholamban
CC       (PLN); the interaction inhibits ATP2A2 Ca(2+) affinity
CC       (PubMed:28890335). Interacts with myoregulin (MRLN) (By similarity).
CC       Interacts with DWORF (By similarity). Interacts with HAX1
CC       (PubMed:18971376). Interacts with S100A8 and S100A9 (By similarity).
CC       Interacts with SLC35G1 and STIM1 (PubMed:22084111). Interacts with
CC       TMEM203 (PubMed:25996873). Interacts with TMEM64 and PDIA3 (By
CC       similarity). Interacts with TMX2. Interacts with VMP1; VMP1 competes
CC       with PLN and SLN to prevent them from forming an inhibitory complex
CC       with ATP2A2 (PubMed:28890335). Interacts with ULK1 (PubMed:28890335).
CC       {ECO:0000250|UniProtKB:O55143, ECO:0000250|UniProtKB:P04191,
CC       ECO:0000250|UniProtKB:Q8R429, ECO:0000269|PubMed:14749390,
CC       ECO:0000269|PubMed:18971376, ECO:0000269|PubMed:22084111,
CC       ECO:0000269|PubMed:25996873, ECO:0000269|PubMed:28890335,
CC       ECO:0000269|PubMed:31735293}.
CC   -!- SUBUNIT: [Isoform 1]: Interacts with TRAM2 (via C-terminus).
CC       {ECO:0000269|PubMed:14749390}.
CC   -!- INTERACTION:
CC       P16615; P55085: F2RL1; NbExp=2; IntAct=EBI-358933, EBI-4303189;
CC       P16615; P41143: OPRD1; NbExp=3; IntAct=EBI-358933, EBI-2624456;
CC       P16615-1; P13569: CFTR; NbExp=6; IntAct=EBI-11613988, EBI-349854;
CC       P16615-1; E2JF22: Piezo1; Xeno; NbExp=2; IntAct=EBI-11613988, EBI-9837938;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:O55143}; Multi-pass membrane protein
CC       {ECO:0000255}. Sarcoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:O55143}; Multi-pass membrane protein
CC       {ECO:0000255}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC         Comment=SERCA2 transcripts differ only in their 3'-UTR region and are
CC         expressed in a tissue-specific manner.;
CC       Name=1; Synonyms=ATP2A2B, Class 2-4, HK1, SERCA2b;
CC         IsoId=P16615-1; Sequence=Displayed;
CC       Name=2; Synonyms=ATP2A2A, Class 1, HK2, SERCA2a;
CC         IsoId=P16615-2; Sequence=VSP_000358;
CC       Name=3; Synonyms=SERCA2C;
CC         IsoId=P16615-3; Sequence=VSP_039393;
CC       Name=4;
CC         IsoId=P16615-4; Sequence=VSP_039392;
CC       Name=5;
CC         IsoId=P16615-5; Sequence=VSP_039394;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is widely expressed in smooth muscle and
CC       nonmuscle tissues such as in adult skin epidermis, with highest
CC       expression in liver, pancreas and lung, and intermediate expression in
CC       brain, kidney and placenta. Also expressed at lower levels in heart and
CC       skeletal muscle. Isoforms 2 and 3 are highly expressed in the heart and
CC       slow twitch skeletal muscle. Expression of isoform 3 is predominantly
CC       restricted to cardiomyocytes and in close proximity to the sarcolemma.
CC       Both isoforms are mildly expressed in lung, kidney, liver, pancreas and
CC       placenta. Expression of isoform 3 is amplified during monocytic
CC       differentiation and also observed in the fetal heart.
CC       {ECO:0000269|PubMed:10441324, ECO:0000269|PubMed:12659872,
CC       ECO:0000269|PubMed:16402920}.
CC   -!- DOMAIN: Ca(2+) and ATP binding cause major rearrangements of the
CC       cytoplasmic and transmembrane domains. According to the E1-E2 model,
CC       Ca(2+) binding to the cytosolic domain of the pump in the high-affinity
CC       E1 conformation is followed by the ATP-dependent phosphorylation of the
CC       active site Asp, giving rise to E1P. A conformational change of the
CC       phosphoenzyme gives rise to the low-affinity E2P state that exposes the
CC       Ca(2+) ions to the lumenal side and promotes Ca(2+) release.
CC       Dephosphorylation of the active site Asp mediates the subsequent return
CC       to the E1 conformation. {ECO:0000250|UniProtKB:P04191}.
CC   -!- DOMAIN: PLN and SLN both have a single transmembrane helix; both occupy
CC       a similar binding site that is situated between the ATP2A2
CC       transmembrane helices. {ECO:0000250|UniProtKB:P04191}.
CC   -!- PTM: Nitrated under oxidative stress. Nitration on the two tyrosine
CC       residues inhibits catalytic activity. {ECO:0000269|PubMed:16399855}.
CC   -!- PTM: Serotonylated on Gln residues by TGM2 in response to hypoxia,
CC       leading to its inactivation. {ECO:0000250|UniProtKB:O55143}.
CC   -!- DISEASE: Acrokeratosis verruciformis (AKV) [MIM:101900]: A localized
CC       disorder of keratinization, which is inherited as an autosomal dominant
CC       trait. Its onset is early in life with multiple flat-topped, flesh-
CC       colored papules on the hands and feet, punctate keratoses on the palms
CC       and soles, with varying degrees of nail involvement. The histopathology
CC       shows a distinctive pattern of epidermal features with hyperkeratosis,
CC       hypergranulosis and acanthosis together with papillomatosis. These
CC       changes are frequently associated with circumscribed elevations of the
CC       epidermis that are said to resemble church spires. There are no
CC       features of dyskeratosis or acantholysis, the typical findings in
CC       lesions of Darier disease. {ECO:0000269|PubMed:12542527}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Darier disease (DD) [MIM:124200]: A skin disorder
CC       characterized by warty papules and plaques in seborrheic areas (central
CC       trunk, flexures, scalp and forehead), palmoplantar pits and distinctive
CC       nail abnormalities. It is due to loss of adhesion between epidermal
CC       cells (acantholysis) and abnormal keratinization. Patients with mild
CC       disease may have no more than a few scattered keratotic papules or
CC       subtle nail changes, whereas those with severe disease are handicapped
CC       by widespread malodorous keratotic plaques. Some patients present with
CC       hemorrhage into acantholytic vesicles on the palms and dorsal aspects
CC       of the fingers which gives rise to black macules. In a few families
CC       affected by Darier disease, neuropsychiatric abnormalities such as mild
CC       mental retardation, schizophrenia, bipolar disorder and epilepsy have
CC       been reported. Stress, UV exposure, heat, sweat, friction and oral
CC       contraception exacerbate disease symptoms. Clinical variants of Darier
CC       disease include hypertrophic, vesicobullous, hypopigmented, cornifying,
CC       zosteriform or linear, acute and comedonal subtypes. Comedonal Darier
CC       disease is characterized by the coexistence of acne-like comedonal
CC       lesions with typical Darier hyperkeratotic papules on light-exposed
CC       areas. At histopathologic level, comedonal Darier disease differs from
CC       classic Darier disease in the prominent follicular involvement and the
CC       presence of greatly elongated dermal villi.
CC       {ECO:0000269|PubMed:10080178, ECO:0000269|PubMed:10441323,
CC       ECO:0000269|PubMed:10441324, ECO:0000269|PubMed:10441325,
CC       ECO:0000269|PubMed:19995371, ECO:0000269|PubMed:28035777}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: [Isoform 1]: Ubiquitous housekeeping isoform.
CC   -!- MISCELLANEOUS: [Isoform 2]: Cardiac/slow twitch, muscle specific
CC       isoform. Has a lower affinity for calcium and a higher catalytic
CC       turnover rate. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: May be due to intron retention. Shows a
CC       lower apparent affinity for cytosolic calcium than isoform 2 and a
CC       catalytic turnover rate similar to isoform 1. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type) (TC 3.A.3)
CC       family. Type IIA subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG57266.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M23114; AAA53193.1; -; mRNA.
DR   EMBL; M23116; AAA52757.1; -; Genomic_DNA.
DR   EMBL; M23115; AAA53194.1; -; mRNA.
DR   EMBL; M23278; AAA52758.1; -; Genomic_DNA.
DR   EMBL; M23116; AAA52758.1; JOINED; Genomic_DNA.
DR   EMBL; AC006088; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC035588; AAH35588.1; -; mRNA.
DR   EMBL; AK293877; BAG57266.1; ALT_INIT; mRNA.
DR   EMBL; AY186578; AAO47398.1; -; mRNA.
DR   CCDS; CCDS9143.1; -. [P16615-2]
DR   CCDS; CCDS9144.1; -. [P16615-1]
DR   PIR; A31981; A31981.
DR   PIR; B31981; B31981.
DR   RefSeq; NP_001672.1; NM_001681.3. [P16615-2]
DR   RefSeq; NP_733765.1; NM_170665.3. [P16615-1]
DR   RefSeq; XP_005253945.1; XM_005253888.2. [P16615-3]
DR   RefSeq; XP_011536704.1; XM_011538402.2. [P16615-3]
DR   PDB; 5ZTF; X-ray; 3.45 A; A=1-1042.
DR   PDB; 6JJU; X-ray; 3.20 A; A=1-993.
DR   PDB; 6LLE; EM; 2.90 A; A=1-1042.
DR   PDB; 6LLY; EM; 2.80 A; A=1-1042.
DR   PDB; 6LN5; EM; 2.80 A; A=1-1031.
DR   PDB; 6LN6; EM; 2.90 A; A=1-1031.
DR   PDB; 6LN7; EM; 2.80 A; A=1-1031.
DR   PDB; 6LN8; EM; 3.10 A; A=1-1031.
DR   PDB; 6LN9; EM; 3.40 A; A=1-1031.
DR   PDB; 7BT2; X-ray; 3.00 A; A=1-993.
DR   PDBsum; 5ZTF; -.
DR   PDBsum; 6JJU; -.
DR   PDBsum; 6LLE; -.
DR   PDBsum; 6LLY; -.
DR   PDBsum; 6LN5; -.
DR   PDBsum; 6LN6; -.
DR   PDBsum; 6LN7; -.
DR   PDBsum; 6LN8; -.
DR   PDBsum; 6LN9; -.
DR   PDBsum; 7BT2; -.
DR   BMRB; P16615; -.
DR   SMR; P16615; -.
DR   BioGRID; 106978; 232.
DR   CORUM; P16615; -.
DR   DIP; DIP-33868N; -.
DR   IntAct; P16615; 121.
DR   MINT; P16615; -.
DR   STRING; 9606.ENSP00000440045; -.
DR   ChEMBL; CHEMBL3901; -.
DR   DrugBank; DB01189; Desflurane.
DR   DrugBank; DB06157; Istaroxime.
DR   TCDB; 3.A.3.2.7; the p-type atpase (p-atpase) superfamily.
DR   iPTMnet; P16615; -.
DR   MetOSite; P16615; -.
DR   PhosphoSitePlus; P16615; -.
DR   SwissPalm; P16615; -.
DR   BioMuta; ATP2A2; -.
DR   DMDM; 114312; -.
DR   EPD; P16615; -.
DR   jPOST; P16615; -.
DR   MassIVE; P16615; -.
DR   MaxQB; P16615; -.
DR   PaxDb; P16615; -.
DR   PeptideAtlas; P16615; -.
DR   PRIDE; P16615; -.
DR   ProteomicsDB; 53385; -. [P16615-1]
DR   ProteomicsDB; 53386; -. [P16615-2]
DR   ProteomicsDB; 53387; -. [P16615-3]
DR   ProteomicsDB; 53388; -. [P16615-4]
DR   ProteomicsDB; 53389; -. [P16615-5]
DR   Antibodypedia; 18505; 422 antibodies.
DR   Ensembl; ENST00000308664; ENSP00000311186; ENSG00000174437. [P16615-2]
DR   Ensembl; ENST00000539276; ENSP00000440045; ENSG00000174437. [P16615-1]
DR   GeneID; 488; -.
DR   KEGG; hsa:488; -.
DR   UCSC; uc001tqk.5; human. [P16615-1]
DR   CTD; 488; -.
DR   DisGeNET; 488; -.
DR   GeneCards; ATP2A2; -.
DR   HGNC; HGNC:812; ATP2A2.
DR   HPA; ENSG00000174437; Group enriched (heart muscle, skeletal muscle).
DR   MalaCards; ATP2A2; -.
DR   MIM; 101900; phenotype.
DR   MIM; 108740; gene.
DR   MIM; 124200; phenotype.
DR   neXtProt; NX_P16615; -.
DR   OpenTargets; ENSG00000174437; -.
DR   Orphanet; 79151; Acrokeratosis verruciformis of Hopf.
DR   Orphanet; 218; Darier disease.
DR   PharmGKB; PA71; -.
DR   VEuPathDB; HostDB:ENSG00000174437.16; -.
DR   eggNOG; KOG0202; Eukaryota.
DR   GeneTree; ENSGT00940000159986; -.
DR   InParanoid; P16615; -.
DR   OMA; DPPTPLW; -.
DR   OrthoDB; 646662at2759; -.
DR   PhylomeDB; P16615; -.
DR   TreeFam; TF300651; -.
DR   PathwayCommons; P16615; -.
DR   Reactome; R-HSA-1912420; Pre-NOTCH Processing in Golgi.
DR   Reactome; R-HSA-418359; Reduction of cytosolic Ca++ levels.
DR   Reactome; R-HSA-5578775; Ion homeostasis.
DR   Reactome; R-HSA-936837; Ion transport by P-type ATPases.
DR   SignaLink; P16615; -.
DR   SIGNOR; P16615; -.
DR   BioGRID-ORCS; 488; 770 hits in 996 CRISPR screens.
DR   ChiTaRS; ATP2A2; human.
DR   GenomeRNAi; 488; -.
DR   Pharos; P16615; Tbio.
DR   PRO; PR:P16615; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; P16615; protein.
DR   Bgee; ENSG00000174437; Expressed in heart right ventricle and 254 other tissues.
DR   ExpressionAtlas; P16615; baseline and differential.
DR   Genevisible; P16615; HS.
DR   GO; GO:0061831; C:apical ectoplasmic specialization; IEA:Ensembl.
DR   GO; GO:0090534; C:calcium ion-transporting ATPase complex; IDA:BHF-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0014801; C:longitudinal sarcoplasmic reticulum; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; IDA:MGI.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0120025; C:plasma membrane bounded cell projection; IEA:Ensembl.
DR   GO; GO:0031095; C:platelet dense tubular network membrane; TAS:Reactome.
DR   GO; GO:0032991; C:protein-containing complex; IEA:Ensembl.
DR   GO; GO:0097470; C:ribbon synapse; IEA:Ensembl.
DR   GO; GO:0016529; C:sarcoplasmic reticulum; IDA:BHF-UCL.
DR   GO; GO:0033017; C:sarcoplasmic reticulum membrane; IBA:GO_Central.
DR   GO; GO:0012506; C:vesicle membrane; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATPase activity; IBA:GO_Central.
DR   GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL.
DR   GO; GO:0005388; F:calcium transmembrane transporter activity, phosphorylative mechanism; IDA:BHF-UCL.
DR   GO; GO:0086039; F:calcium-transporting ATPase activity involved in regulation of cardiac muscle cell membrane potential; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0044325; F:ion channel binding; IPI:ARUK-UCL.
DR   GO; GO:0031775; F:lutropin-choriogonadotropic hormone receptor binding; IEA:Ensembl.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0008553; F:proton-exporting ATPase activity, phosphorylative mechanism; IBA:GO_Central.
DR   GO; GO:0044548; F:S100 protein binding; IPI:UniProtKB.
DR   GO; GO:0000045; P:autophagosome assembly; IDA:UniProtKB.
DR   GO; GO:0016240; P:autophagosome membrane docking; IDA:UniProtKB.
DR   GO; GO:1990036; P:calcium ion import into sarcoplasmic reticulum; ISS:BHF-UCL.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; IDA:BHF-UCL.
DR   GO; GO:1903515; P:calcium ion transport from cytosol to endoplasmic reticulum; IDA:BHF-UCL.
DR   GO; GO:0014898; P:cardiac muscle hypertrophy in response to stress; IEA:Ensembl.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:BHF-UCL.
DR   GO; GO:0034605; P:cellular response to heat; IEA:Ensembl.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0032469; P:endoplasmic reticulum calcium ion homeostasis; IDA:BHF-UCL.
DR   GO; GO:0008544; P:epidermis development; TAS:ProtInc.
DR   GO; GO:0006984; P:ER-nucleus signaling pathway; IEA:Ensembl.
DR   GO; GO:0034220; P:ion transmembrane transport; TAS:Reactome.
DR   GO; GO:1990456; P:mitochondrion-endoplasmic reticulum membrane tethering; IDA:UniProtKB.
DR   GO; GO:0045822; P:negative regulation of heart contraction; IEA:Ensembl.
DR   GO; GO:1900121; P:negative regulation of receptor binding; IMP:ARUK-UCL.
DR   GO; GO:0140056; P:organelle localization by membrane tethering; IDA:UniProtKB.
DR   GO; GO:0032470; P:positive regulation of endoplasmic reticulum calcium ion concentration; IDA:BHF-UCL.
DR   GO; GO:0010460; P:positive regulation of heart rate; TAS:BHF-UCL.
DR   GO; GO:1903233; P:regulation of calcium ion-dependent exocytosis of neurotransmitter; IEA:Ensembl.
DR   GO; GO:1903779; P:regulation of cardiac conduction; TAS:Reactome.
DR   GO; GO:0098909; P:regulation of cardiac muscle cell action potential involved in regulation of contraction; ISS:BHF-UCL.
DR   GO; GO:0086036; P:regulation of cardiac muscle cell membrane potential; ISS:BHF-UCL.
DR   GO; GO:0010882; P:regulation of cardiac muscle contraction by calcium ion signaling; IDA:BHF-UCL.
DR   GO; GO:0002026; P:regulation of the force of heart contraction; IEA:Ensembl.
DR   GO; GO:0055119; P:relaxation of cardiac muscle; IDA:BHF-UCL.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0070296; P:sarcoplasmic reticulum calcium ion transport; TAS:BHF-UCL.
DR   GO; GO:0003009; P:skeletal muscle contraction; IEA:Ensembl.
DR   GO; GO:0033292; P:T-tubule organization; IEA:Ensembl.
DR   GO; GO:0014883; P:transition between fast and slow fiber; IEA:Ensembl.
DR   Gene3D; 3.40.1110.10; -; 1.
DR   Gene3D; 3.40.50.1000; -; 1.
DR   InterPro; IPR006068; ATPase_P-typ_cation-transptr_C.
DR   InterPro; IPR004014; ATPase_P-typ_cation-transptr_N.
DR   InterPro; IPR023299; ATPase_P-typ_cyto_dom_N.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR023298; ATPase_P-typ_TM_dom_sf.
DR   InterPro; IPR008250; ATPase_P-typ_transduc_dom_A_sf.
DR   InterPro; IPR036412; HAD-like_sf.
DR   InterPro; IPR023214; HAD_sf.
DR   InterPro; IPR005782; P-type_ATPase_IIA.
DR   InterPro; IPR001757; P_typ_ATPase.
DR   InterPro; IPR044492; P_typ_ATPase_HD_dom.
DR   Pfam; PF00689; Cation_ATPase_C; 1.
DR   Pfam; PF00690; Cation_ATPase_N; 1.
DR   PRINTS; PR00120; HATPASE.
DR   SFLD; SFLDF00027; p-type_atpase; 1.
DR   SMART; SM00831; Cation_ATPase_N; 1.
DR   SUPFAM; SSF56784; SSF56784; 1.
DR   SUPFAM; SSF81653; SSF81653; 1.
DR   SUPFAM; SSF81660; SSF81660; 1.
DR   SUPFAM; SSF81665; SSF81665; 1.
DR   TIGRFAMs; TIGR01116; ATPase-IIA1_Ca; 1.
DR   TIGRFAMs; TIGR01494; ATPase_P-type; 2.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Calcium;
KW   Calcium transport; Disease variant; Disulfide bond; Endoplasmic reticulum;
KW   Epilepsy; Ion transport; Magnesium; Membrane; Metal-binding; Nitration;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Sarcoplasmic reticulum; Translocase; Transmembrane; Transmembrane helix;
KW   Transport.
FT   CHAIN           1..1042
FT                   /note="Sarcoplasmic/endoplasmic reticulum calcium ATPase 2"
FT                   /id="PRO_0000046196"
FT   TOPO_DOM        1..48
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        49..69
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250|UniProtKB:P04191"
FT   TOPO_DOM        70..89
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        90..110
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250|UniProtKB:P04191"
FT   TOPO_DOM        111..253
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        254..273
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250|UniProtKB:P04191"
FT   TOPO_DOM        274..295
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        296..313
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250|UniProtKB:P04191"
FT   TOPO_DOM        314..756
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        757..776
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250|UniProtKB:P04191"
FT   TOPO_DOM        777..786
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        787..807
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250|UniProtKB:P04191"
FT   TOPO_DOM        808..827
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        828..850
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250|UniProtKB:P04191"
FT   TOPO_DOM        851..896
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        897..916
FT                   /note="Helical; Name=8"
FT                   /evidence="ECO:0000250|UniProtKB:P04191"
FT   TOPO_DOM        917..929
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        930..948
FT                   /note="Helical; Name=9"
FT                   /evidence="ECO:0000250|UniProtKB:P04191"
FT   TOPO_DOM        949..963
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        964..984
FT                   /note="Helical; Name=10"
FT                   /evidence="ECO:0000250|UniProtKB:P04191"
FT   TOPO_DOM        985..1042
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   REGION          575..594
FT                   /note="Interaction with HAX1"
FT                   /evidence="ECO:0000269|PubMed:18971376"
FT   REGION          787..807
FT                   /note="Interaction with PLN"
FT                   /evidence="ECO:0000250|UniProtKB:P04191"
FT   REGION          788..1042
FT                   /note="Interaction with TMEM64 and PDIA3"
FT                   /evidence="ECO:0000250|UniProtKB:O55143"
FT   REGION          931..942
FT                   /note="Interaction with PLN"
FT                   /evidence="ECO:0000250|UniProtKB:P04191"
FT   ACT_SITE        351
FT                   /note="4-aspartylphosphate intermediate"
FT                   /evidence="ECO:0000250|UniProtKB:P04191"
FT   METAL           304
FT                   /note="Calcium 1; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   METAL           305
FT                   /note="Calcium 1; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   METAL           307
FT                   /note="Calcium 1; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   METAL           309
FT                   /note="Calcium 1"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   METAL           351
FT                   /note="Magnesium"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   METAL           353
FT                   /note="Magnesium; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   METAL           702
FT                   /note="Magnesium"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   METAL           767
FT                   /note="Calcium 2"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   METAL           770
FT                   /note="Calcium 2"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   METAL           795
FT                   /note="Calcium 1"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   METAL           798
FT                   /note="Calcium 2"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   METAL           799
FT                   /note="Calcium 1"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   METAL           799
FT                   /note="Calcium 2"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   METAL           907
FT                   /note="Calcium 2"
FT                   /evidence="ECO:0000250|UniProtKB:P04191"
FT   BINDING         353
FT                   /note="ATP"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   BINDING         442
FT                   /note="ATP"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   BINDING         489
FT                   /note="ATP"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   BINDING         514
FT                   /note="ATP"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   BINDING         559
FT                   /note="ATP"
FT                   /evidence="ECO:0000250|UniProtKB:P04191"
FT   BINDING         677
FT                   /note="ATP"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   BINDING         683
FT                   /note="ATP"
FT                   /evidence="ECO:0000250|UniProtKB:P04191"
FT   BINDING         705
FT                   /note="ATP"
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   MOD_RES         38
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O55143"
FT   MOD_RES         294
FT                   /note="3'-nitrotyrosine"
FT                   /evidence="ECO:0000269|PubMed:16399855"
FT   MOD_RES         295
FT                   /note="3'-nitrotyrosine"
FT                   /evidence="ECO:0000269|PubMed:16399855"
FT   MOD_RES         441
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64578"
FT   MOD_RES         531
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O55143"
FT   MOD_RES         580
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         663
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   DISULFID        875..887
FT                   /evidence="ECO:0000250|UniProtKB:P11607"
FT   VAR_SEQ         155..181
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_039392"
FT   VAR_SEQ         994..1042
FT                   /note="GKECVQPATKSCSFSACTDGISWPFVLLIMPLVIWVYSTDTNFSDMFWS ->
FT                   AILE (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:2844796"
FT                   /id="VSP_000358"
FT   VAR_SEQ         994..1042
FT                   /note="GKECVQPATKSCSFSACTDGISWPFVLLIMPLVIWVYSTDTNFSDMFWS ->
FT                   VLSSEL (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:12659872"
FT                   /id="VSP_039393"
FT   VAR_SEQ         994..1042
FT                   /note="GKECVQPATKSCSFSACTDGISWPFVLLIMPLVIWVYSTDTNFSDMFWS ->
FT                   DIIK (in isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_039394"
FT   VARIANT         23
FT                   /note="G -> E (in DD; dbSNP:rs28929478)"
FT                   /evidence="ECO:0000269|PubMed:10080178"
FT                   /id="VAR_008608"
FT   VARIANT         39
FT                   /note="N -> T (in DD)"
FT                   /evidence="ECO:0000269|PubMed:10441325"
FT                   /id="VAR_008609"
FT   VARIANT         41
FT                   /note="Missing (in DD; comedonal type)"
FT                   /evidence="ECO:0000269|PubMed:19995371"
FT                   /id="VAR_063398"
FT   VARIANT         47
FT                   /note="K -> KMFLTGK (in DD)"
FT                   /id="VAR_008610"
FT   VARIANT         65
FT                   /note="L -> S (in DD; severe form)"
FT                   /id="VAR_008611"
FT   VARIANT         74..108
FT                   /note="Missing (in DD)"
FT                   /evidence="ECO:0000269|PubMed:28035777"
FT                   /id="VAR_079685"
FT   VARIANT         101
FT                   /note="N -> S (in DD)"
FT                   /evidence="ECO:0000269|PubMed:28035777"
FT                   /id="VAR_079686"
FT   VARIANT         131
FT                   /note="R -> Q (in DD; dbSNP:rs121912738)"
FT                   /evidence="ECO:0000269|PubMed:28035777"
FT                   /id="VAR_008612"
FT   VARIANT         160
FT                   /note="P -> L (in DD)"
FT                   /id="VAR_008613"
FT   VARIANT         186
FT                   /note="S -> P (in DD)"
FT                   /id="VAR_008614"
FT   VARIANT         194..197
FT                   /note="Missing (in DD)"
FT                   /evidence="ECO:0000269|PubMed:28035777"
FT                   /id="VAR_079687"
FT   VARIANT         211
FT                   /note="G -> D (in DD; severe form)"
FT                   /id="VAR_008615"
FT   VARIANT         223
FT                   /note="V -> M (in DD)"
FT                   /id="VAR_008616"
FT   VARIANT         268
FT                   /note="C -> F (in DD; haemorrhagic lesions;
FT                   dbSNP:rs121912733)"
FT                   /id="VAR_008617"
FT   VARIANT         310
FT                   /note="G -> V (in DD)"
FT                   /id="VAR_008618"
FT   VARIANT         318
FT                   /note="C -> R (in DD; severe form)"
FT                   /id="VAR_008619"
FT   VARIANT         348
FT                   /note="I -> T (in DD)"
FT                   /id="VAR_008620"
FT   VARIANT         357
FT                   /note="T -> K (in DD)"
FT                   /evidence="ECO:0000269|PubMed:10080178"
FT                   /id="VAR_009508"
FT   VARIANT         412
FT                   /note="E -> G (in DD)"
FT                   /id="VAR_008621"
FT   VARIANT         495
FT                   /note="S -> F (in DD)"
FT                   /evidence="ECO:0000269|PubMed:10080178"
FT                   /id="VAR_008622"
FT   VARIANT         560
FT                   /note="C -> R (in DD; neuropsychiatric phenotype;
FT                   dbSNP:rs121912734)"
FT                   /evidence="ECO:0000269|PubMed:10441325"
FT                   /id="VAR_008623"
FT   VARIANT         590
FT                   /note="L -> P (in DD)"
FT                   /evidence="ECO:0000269|PubMed:28035777"
FT                   /id="VAR_079688"
FT   VARIANT         602
FT                   /note="P -> L (in AKV; loss of activity;
FT                   dbSNP:rs121912737)"
FT                   /evidence="ECO:0000269|PubMed:12542527"
FT                   /id="VAR_017532"
FT   VARIANT         625
FT                   /note="G -> A (in DD)"
FT                   /evidence="ECO:0000269|PubMed:28035777"
FT                   /id="VAR_079689"
FT   VARIANT         626
FT                   /note="D -> E (in DD)"
FT                   /evidence="ECO:0000269|PubMed:28035777"
FT                   /id="VAR_079690"
FT   VARIANT         666..1042
FT                   /note="Missing (in DD)"
FT                   /evidence="ECO:0000269|PubMed:28035777"
FT                   /id="VAR_079691"
FT   VARIANT         672
FT                   /note="A -> P (in DD)"
FT                   /evidence="ECO:0000269|PubMed:28035777"
FT                   /id="VAR_079692"
FT   VARIANT         675
FT                   /note="F -> S (in DD; multiple neuropsychiatric features)"
FT                   /id="VAR_008624"
FT   VARIANT         683
FT                   /note="K -> E (in DD; depression)"
FT                   /id="VAR_008625"
FT   VARIANT         691
FT                   /note="Q -> P (in DD)"
FT                   /evidence="ECO:0000269|PubMed:28035777"
FT                   /id="VAR_079693"
FT   VARIANT         702
FT                   /note="D -> N (in DD; moderate form)"
FT                   /id="VAR_008626"
FT   VARIANT         745
FT                   /note="A -> D (in DD; moderate form)"
FT                   /id="VAR_008627"
FT   VARIANT         749
FT                   /note="G -> R (in DD)"
FT                   /evidence="ECO:0000269|PubMed:10080178"
FT                   /id="VAR_009509"
FT   VARIANT         750
FT                   /note="R -> W (in DD)"
FT                   /evidence="ECO:0000269|PubMed:28035777"
FT                   /id="VAR_079694"
FT   VARIANT         754
FT                   /note="Missing (in DD)"
FT                   /id="VAR_008628"
FT   VARIANT         765
FT                   /note="S -> L (in DD)"
FT                   /evidence="ECO:0000269|PubMed:10441325"
FT                   /id="VAR_008629"
FT   VARIANT         765
FT                   /note="S -> W (in DD)"
FT                   /evidence="ECO:0000269|PubMed:28035777"
FT                   /id="VAR_079695"
FT   VARIANT         767
FT                   /note="N -> S (in DD; haemorrhagic lesions and
FT                   neuropsychiatric phenotype; dbSNP:rs121912732)"
FT                   /id="VAR_008630"
FT   VARIANT         769
FT                   /note="G -> R (in DD; dbSNP:rs121912736)"
FT                   /id="VAR_008631"
FT   VARIANT         803
FT                   /note="A -> T (in DD; mild/moderate form)"
FT                   /id="VAR_008632"
FT   VARIANT         838
FT                   /note="A -> P (in DD; severe form; petit mal epilepsy)"
FT                   /id="VAR_008633"
FT   VARIANT         843
FT                   /note="V -> F (in DD; depression)"
FT                   /id="VAR_008634"
FT   VARIANT         849
FT                   /note="G -> GG (in DD)"
FT                   /evidence="ECO:0000269|PubMed:28035777"
FT                   /id="VAR_079696"
FT   VARIANT         875
FT                   /note="C -> G (in DD; retinitis pigmentosa)"
FT                   /id="VAR_008635"
FT   VARIANT         900
FT                   /note="L -> P (in DD)"
FT                   /evidence="ECO:0000269|PubMed:28035777"
FT                   /id="VAR_079697"
FT   VARIANT         920
FT                   /note="S -> Y (in DD; mild/moderate/severe form; one
FT                   patient with epilepsy)"
FT                   /id="VAR_008636"
FT   VARIANT         943
FT                   /note="H -> R (in DD; learning difficulties)"
FT                   /evidence="ECO:0000269|PubMed:28035777"
FT                   /id="VAR_008637"
FT   VARIANT         975
FT                   /note="P -> R (in DD)"
FT                   /id="VAR_008638"
FT   MUTAGEN         256
FT                   /note="F->V: No effect on interaction with VMP1."
FT                   /evidence="ECO:0000269|PubMed:28890335"
FT   TURN            4..6
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           9..16
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   TURN            20..22
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           26..35
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           52..55
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           56..58
FT                   /evidence="ECO:0007744|PDB:5ZTF"
FT   TURN            61..63
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           64..71
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           74..78
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   TURN            85..90
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           91..121
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          126..131
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          132..136
FT                   /evidence="ECO:0007744|PDB:5ZTF"
FT   STRAND          138..141
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           142..144
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          150..154
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          161..168
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          174..176
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   TURN            178..180
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          184..188
FT                   /evidence="ECO:0007744|PDB:5ZTF"
FT   TURN            201..203
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          213..216
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          218..225
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           227..229
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           231..235
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           248..272
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           273..275
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   TURN            282..285
FT                   /evidence="ECO:0007744|PDB:6JJU"
FT   HELIX           288..291
FT                   /evidence="ECO:0007744|PDB:6JJU"
FT   HELIX           294..306
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           311..328
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          331..334
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           337..343
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          347..352
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   TURN            353..356
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          362..373
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          376..384
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          387..391
FT                   /evidence="ECO:0007744|PDB:6JJU"
FT   STRAND          395..397
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           404..406
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           408..419
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          424..428
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   TURN            429..432
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          433..438
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           440..452
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   TURN            464..469
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           470..478
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          479..488
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   TURN            489..492
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          493..502
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          504..506
FT                   /evidence="ECO:0007744|PDB:6JJU"
FT   STRAND          510..515
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           517..522
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          524..529
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          532..535
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           538..553
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          554..556
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          559..568
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           572..574
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           580..582
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           583..586
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          589..599
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           606..615
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          619..623
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           628..637
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          639..641
FT                   /evidence="ECO:0007744|PDB:6JJU"
FT   TURN            648..650
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          651..653
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           654..658
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           662..671
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          674..677
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           680..692
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          697..701
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           704..706
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           707..712
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          713..719
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           724..728
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          731..734
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           739..779
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           788..796
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   TURN            797..799
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           800..806
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   TURN            813..816
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          823..825
FT                   /evidence="ECO:0007744|PDB:6JJU"
FT   HELIX           830..856
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          859..861
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           866..870
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           872..874
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           880..882
FT                   /evidence="ECO:0007744|PDB:5ZTF"
FT   HELIX           888..890
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           893..913
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   STRAND          916..918
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   TURN            921..923
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           926..928
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           930..944
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   TURN            945..947
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           951..955
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           963..973
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           975..988
FT                   /evidence="ECO:0007744|PDB:7BT2"
FT   HELIX           1019..1029
FT                   /evidence="ECO:0007744|PDB:5ZTF"
SQ   SEQUENCE   1042 AA;  114757 MW;  5462FF2DA7FB630A CRC64;
     MENAHTKTVE EVLGHFGVNE STGLSLEQVK KLKERWGSNE LPAEEGKTLL ELVIEQFEDL
     LVRILLLAAC ISFVLAWFEE GEETITAFVE PFVILLILVA NAIVGVWQER NAENAIEALK
     EYEPEMGKVY RQDRKSVQRI KAKDIVPGDI VEIAVGDKVP ADIRLTSIKS TTLRVDQSIL
     TGESVSVIKH TDPVPDPRAV NQDKKNMLFS GTNIAAGKAM GVVVATGVNT EIGKIRDEMV
     ATEQERTPLQ QKLDEFGEQL SKVISLICIA VWIINIGHFN DPVHGGSWIR GAIYYFKIAV
     ALAVAAIPEG LPAVITTCLA LGTRRMAKKN AIVRSLPSVE TLGCTSVICS DKTGTLTTNQ
     MSVCRMFILD RVEGDTCSLN EFTITGSTYA PIGEVHKDDK PVNCHQYDGL VELATICALC
     NDSALDYNEA KGVYEKVGEA TETALTCLVE KMNVFDTELK GLSKIERANA CNSVIKQLMK
     KEFTLEFSRD RKSMSVYCTP NKPSRTSMSK MFVKGAPEGV IDRCTHIRVG STKVPMTSGV
     KQKIMSVIRE WGSGSDTLRC LALATHDNPL RREEMHLEDS ANFIKYETNL TFVGCVGMLD
     PPRIEVASSV KLCRQAGIRV IMITGDNKGT AVAICRRIGI FGQDEDVTSK AFTGREFDEL
     NPSAQRDACL NARCFARVEP SHKSKIVEFL QSFDEITAMT GDGVNDAPAL KKAEIGIAMG
     SGTAVAKTAS EMVLADDNFS TIVAAVEEGR AIYNNMKQFI RYLISSNVGE VVCIFLTAAL
     GFPEALIPVQ LLWVNLVTDG LPATALGFNP PDLDIMNKPP RNPKEPLISG WLFFRYLAIG
     CYVGAATVGA AAWWFIAADG GPRVSFYQLS HFLQCKEDNP DFEGVDCAIF ESPYPMTMAL
     SVLVTIEMCN ALNSLSENQS LLRMPPWENI WLVGSICLSM SLHFLILYVE PLPLIFQITP
     LNVTQWLMVL KISLPVILMD ETLKFVARNY LEPGKECVQP ATKSCSFSAC TDGISWPFVL
     LIMPLVIWVY STDTNFSDMF WS
//
